To the Editor: Tumor-induced osteomalacia (TIO) is an extremely rare paraneoplastic syndrome that is characterized by hypophosphatemia and hyperphosphaturia. [1] Since TIO was first described in 1947, more than 500 cases have been reported worldwide. [2, 3] TIO is an acquired hypophosphatemic osteomalacia caused by decreased phosphorus reabsorption in the renal tubules and increased renal phosphorus excretion. The clinical manifestations of TIO are diverse and non-specific; the most common presentations are progressive bone pain, fracture, skeletal deformity, and movement dysfunction. [1] [2] [3] To date, very few reported cases of TIO have presented with adjacent bone destruction caused by a phosphaturic mesenchymal tumor. Thus, clinicians lack knowledge and experience in prompt diagnosis and reasonable treatment of this rare condition. Herein, we present a case of TIO with substantial bone destruction that was successfully treated surgically [ Figure 1 ].
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A 15-year-old boy presented with a 3-year history of severe systemic multiple bone pain, hypophosphatemia, and mobility impairment. There were no other symptoms, no history of recent trauma or surgery, and no history of the underlying disease. Physical examination showed a decreased muscle strength of 5À/5 grade in the bilateral lower limbs, plus sternal tenderness and thoracic crushing pain. Laboratory tests demonstrated hypophosphatemia, elevated b-C-terminal telopeptide of type I collagen, normal parathyroid hormone level, elevated serum alkaline phosphatase level, and normal 1, 25-dihydroxy vitamin D level. Radiography showed substantial bone destruction in the right distal femur. Magnetic resonance imaging (MRI) revealed a tumor in the right distal femur with irregular hyperintense signals on T1-and T2-weighted imagery. 99 m Tc-Octreotide scanning and 68 Gallium(Ga)-DOTA-TATE positron emission tomography/computed tomography (PET/CT) identified highintake space-occupying lesions in the right distal femur, which was highly suggestive of oncogenic osteomalacia. Analgesic therapy was administered, followed by tumor resection and reconstruction with a knee prosthesis in the right lower extremity. Post-operative radiography showed satisfactory positioning of the prosthesis. The tumor was successfully excised, and pathological results confirmed TIO with a phosphaturic mesenchymal tumor. The serum phosphate level returned to normal post-operatively, and the symptoms improved substantially compared with preoperatively. Moreover, the visual analogue scale score for bone pain improved from 6 to 7 pre-operatively to 1 to 2 post-operatively. The patient declined adjuvant treatment but underwent rehabilitation and outpatient monitoring.
TIO is a paraneoplastic syndrome usually associated with mesenchymal tumors; phosphatonins decrease the renal resorption of phosphate, leading to hypophosphatemia, muscle weakness, and osteomalacia. [1] [2] [3] However, it is extremely rare for a patient with TIO to present with a giant soft tissue mass and substantial destruction of adjacent bones. The methods used to detect TIO include 99 m Tc-Octreotide scanning and 68 Ga-DOTA-TATE PET/ CT. [2, 3] Somatostatin receptor imaging utilizes the characteristics of the somatostatin receptor (SSTR) expression in phosphaturic mesenchymal tumors. The accuracy of 68 Ga-DOTA-TATE PET/CT in diagnosing TIO is 98.0%, which is significantly higher than other detection methods. [2, 3] The final diagnosis depends on the history, clinical manifestations, laboratory tests, imaging, pathological characteristics, and treatment effect. In the present case, the phosphaturic mesenchymal tumor had to be differentiated from neoplasms that commonly involve the femur in this age group, mostly osteosarcoma, and other malignant tumors. In imaging studies, although plain radiography might reflect the radiologic characteristics of the lesion, CT and MRI more accurately assess the extent of the mass within the bone and surrounding soft tissue. The 99 m Tc-Octreotide imaging and 68 Ga-DOTA-TATE PET/CT play a complementary role in obtaining an accurate diagnosis. Pathological results remain the "gold standard" to diagnose and definitively confirm the presence of a phosphaturic mesenchymal tumor. [2, 3] Surgical resection is the optimal treatment option to correct the biochemical abnormalities and remineralize the bone substance in patients with TIO. [4, 5] Surgical resection involves complete surgical excision to remove the pathogenic tumor, and pathological examination to confirm whether the tumor is a phosphaturic mesenchymal tumor. Improper selection of surgical procedures or incomplete resection can lead to the recurrence of the phosphaturic mesenchymal tumor and associated symptoms. [4, 5] The present case highlights the importance of accurate diagnosis and proper treatment for patients with a unique presentation of TIO.
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